| Item Type | Name |
|
Concept
|
Aminopterin
|
|
Concept
|
Adenosine Diphosphate
|
|
Concept
|
Antibiotics, Antineoplastic
|
|
Concept
|
Aged, 80 and over
|
|
Concept
|
Australia
|
|
Concept
|
Azides
|
|
Concept
|
Aged
|
|
Concept
|
Complementary Therapies
|
|
Concept
|
Administration, Oral
|
|
Concept
|
Blood Coagulation
|
|
Concept
|
Androstadienes
|
|
Concept
|
Antifungal Agents
|
|
Concept
|
Antimetabolites, Antineoplastic
|
|
Concept
|
Antineoplastic Combined Chemotherapy Protocols
|
|
Concept
|
Analysis of Variance
|
|
Concept
|
Antibodies, Monoclonal
|
|
Concept
|
Benzamides
|
|
Concept
|
Benzazepines
|
|
Concept
|
Benzimidazoles
|
|
Concept
|
Bayes Theorem
|
|
Concept
|
Bone Neoplasms
|
|
Concept
|
Azacitidine
|
|
Concept
|
Benzodiazepines
|
|
Concept
|
Benzofurans
|
|
Concept
|
Carcinoma, Renal Cell
|
|
Concept
|
Bilirubin
|
|
Concept
|
Bile Duct Neoplasms
|
|
Concept
|
Biopsy
|
|
Concept
|
Body Weight
|
|
Concept
|
Body Weights and Measures
|
|
Concept
|
Bridged-Ring Compounds
|
|
Concept
|
California
|
|
Concept
|
Carcinoma, Basal Cell
|
|
Concept
|
Carcinoma, Non-Small-Cell Lung
|
|
Concept
|
Complement System Proteins
|
|
Concept
|
Chemistry, Physical
|
|
Concept
|
Cell Cycle
|
|
Concept
|
Combined Modality Therapy
|
|
Concept
|
Uterine Cervical Neoplasms
|
|
Concept
|
Chemistry, Pharmaceutical
|
|
Concept
|
Chicago
|
|
Concept
|
gamma-Aminobutyric Acid
|
|
Concept
|
Chromium
|
|
Concept
|
Leucovorin
|
|
Concept
|
Creatinine
|
|
Concept
|
Cricetulus
|
|
Concept
|
Circadian Rhythm
|
|
Concept
|
Interleukin-2
|
|
Concept
|
Cytochrome P-450 Enzyme System
|
|
Concept
|
Dose-Response Relationship, Radiation
|
|
Concept
|
Exercise Therapy
|
|
Concept
|
Cost-Benefit Analysis
|
|
Concept
|
Depression
|
|
Concept
|
Counseling
|
|
Concept
|
Indoles
|
|
Concept
|
Insulin-Like Growth Factor II
|
|
Concept
|
Myasthenia Gravis
|
|
Concept
|
Killer Cells, Natural
|
|
Concept
|
Obesity
|
|
Concept
|
Insulin-Like Growth Factor I
|
|
Concept
|
Enzyme-Linked Immunosorbent Assay
|
|
Concept
|
Flow Cytometry
|
|
Concept
|
Leukocytes, Mononuclear
|
|
Concept
|
Carcinoma, Hepatocellular
|
|
Concept
|
Metformin
|
|
Concept
|
Pharmacogenetics
|
|
Concept
|
Neutropenia
|
|
Concept
|
Immunohistochemistry
|
|
Concept
|
Indazoles
|
|
Concept
|
Ovariectomy
|
|
Concept
|
Methotrexate
|
|
Concept
|
Middle Aged
|
|
Concept
|
Mitoxantrone
|
|
Concept
|
Cricetinae
|
|
Concept
|
Health Services Misuse
|
|
Concept
|
Nigeria
|
|
Concept
|
Osteoporosis
|
|
Concept
|
Ovary
|
|
Concept
|
Safety
|
|
Concept
|
Phosphorylation
|
|
Concept
|
Thrombocytopenia
|
|
Concept
|
Protein Binding
|
|
Concept
|
Gallbladder Neoplasms
|
|
Concept
|
Rectal Neoplasms
|
|
Concept
|
Radiotherapy Planning, Computer-Assisted
|
|
Concept
|
Intestinal Absorption
|
|
Concept
|
Cohort Studies
|
|
Concept
|
Radiodermatitis
|
|
Concept
|
Stress, Psychological
|
|
Concept
|
Humans
|
|
Concept
|
Leukocyte Count
|
|
Concept
|
Body Mass Index
|
|
Concept
|
Transcription, Genetic
|
|
Concept
|
Tretinoin
|
|
Concept
|
Thalidomide
|
|
Concept
|
Suprachiasmatic Nucleus
|
|
Concept
|
Tetrahydrofolates
|
|
Concept
|
United States
|
|
Concept
|
Biomarkers, Tumor
|
|
Concept
|
Tumor Necrosis Factor-alpha
|
|
Concept
|
Vindesine
|
|
Concept
|
Tamoxifen
|
|
Concept
|
Premenopause
|
|
Concept
|
Isoquinolines
|
|
Concept
|
Biomarkers
|
|
Concept
|
Isotretinoin
|
|
Concept
|
CD56 Antigen
|
|
Concept
|
Oligodeoxyribonucleotides, Antisense
|
|
Concept
|
Vitamin D-Binding Protein
|
|
Concept
|
Genes, BRCA2
|
|
Concept
|
Health Behavior
|
|
Concept
|
Lymphocytes, Tumor-Infiltrating
|
|
Concept
|
Case-Control Studies
|
|
Concept
|
Receptor, IGF Type 1
|
|
Concept
|
Postmenopause
|
|
Concept
|
Metoclopramide
|
|
Concept
|
Apoptosis
|
|
Concept
|
Carcinoma, Lobular
|
|
Concept
|
Cell Proliferation
|
|
Concept
|
Antigens, CD34
|
|
Concept
|
Carcinoma, Endometrioid
|
|
Concept
|
Carcinoma, Ductal, Breast
|
|
Concept
|
CA-125 Antigen
|
|
Concept
|
Antineoplastic Agents, Alkylating
|
|
Concept
|
Angiogenesis Inhibitors
|
|
Concept
|
BRCA1 Protein
|
|
Concept
|
Chemokine CXCL9
|
|
Concept
|
Cross-Over Studies
|
|
Concept
|
Immunoconjugates
|
|
Concept
|
Antineoplastic Agents, Hormonal
|
|
Concept
|
Insulin-Like Growth Factor Binding Protein 3
|
|
Concept
|
Collagen Type I
|
|
Concept
|
Ontario
|
|
Concept
|
B7-H1 Antigen
|
|
Concept
|
Vascular Endothelial Growth Factors
|
|
Concept
|
Human papillomavirus 18
|
|
Concept
|
Aromatase Inhibitors
|
|
Concept
|
Tumor Burden
|
|
Concept
|
Proto-Oncogene Proteins c-bcl-2
|
|
Concept
|
Patient Participation
|
|
Concept
|
Glucuronides
|
|
Concept
|
Sentinel Lymph Node Biopsy
|
|
Concept
|
Genes, BRCA1
|
|
Concept
|
Radiotherapy, Conformal
|
|
Concept
|
BRCA2 Protein
|
|
Concept
|
Cyclin-Dependent Kinase Inhibitor p21
|
|
Concept
|
Promoter Regions, Genetic
|
|
Concept
|
Mice
|
|
Concept
|
Pyrazoles
|
|
Concept
|
Quinazolines
|
|
Concept
|
Diphosphates
|
|
Concept
|
Pyrroles
|
|
Concept
|
National Cancer Institute (U.S.)
|
|
Concept
|
Rosaniline Dyes
|
|
Concept
|
South Africa
|
|
Concept
|
Meningeal Carcinomatosis
|
|
Concept
|
Rats
|
|
Concept
|
Chemoradiotherapy
|
|
Concept
|
Triazoles
|
|
Concept
|
Class I Phosphatidylinositol 3-Kinases
|
|
Concept
|
Antibodies, Monoclonal, Humanized
|
|
Concept
|
Vincristine
|
|
Concept
|
Chemokine CXCL10
|
|
Concept
|
T-Lymphocytes, Cytotoxic
|
|
Concept
|
Blotting, Western
|
|
Concept
|
Colorectal Neoplasms
|
|
Concept
|
Multivariate Analysis
|
|
Concept
|
Cyclins
|
|
Concept
|
Cell Death
|
|
Concept
|
Chemotherapy, Adjuvant
|
|
Concept
|
Vinblastine
|
|
Concept
|
Patient Satisfaction
|
|
Concept
|
Hereditary Breast and Ovarian Cancer Syndrome
|
|
Concept
|
ATP-Binding Cassette Transporters
|
|
Concept
|
Receptor, ErbB-2
|
|
Concept
|
Trimetrexate
|
|
Concept
|
Immunoglobulins, Intravenous
|
|
Concept
|
Neoadjuvant Therapy
|
|
Concept
|
Dual Specificity Phosphatase 1
|
|
Concept
|
Stroke
|
|
Concept
|
Breast Neoplasms, Male
|
|
Concept
|
Ki-67 Antigen
|
|
Concept
|
Topotecan
|
|
Concept
|
Transcriptome
|
|
Concept
|
DNA Mismatch Repair
|
|
Concept
|
Citrus paradisi
|
|
Concept
|
RNA, Small Interfering
|
|
Concept
|
Vascular Endothelial Growth Factor A
|
|
Concept
|
Programmed Cell Death 1 Receptor
|
|
Concept
|
Cell Line, Tumor
|
|
Concept
|
Nanomedicine
|
|
Concept
|
Cytochrome P-450 CYP3A
|
|
Concept
|
Human papillomavirus 16
|
|
Concept
|
Drug Discovery
|
|
Concept
|
Epigenomics
|
|
Concept
|
Anilides
|
|
Concept
|
Antineoplastic Agents, Phytogenic
|
|
Concept
|
Benzenesulfonates
|
|
Concept
|
Camptothecin
|
|
Concept
|
Canada
|
|
Concept
|
Chromatin
|
|
Concept
|
Communication
|
|
Concept
|
Data Interpretation, Statistical
|
|
Concept
|
Doxorubicin
|
|
Concept
|
Enhancer Elements, Genetic
|
|
Concept
|
Fever
|
|
Concept
|
Follow-Up Studies
|
|
Concept
|
Genetic Counseling
|
|
Concept
|
Leukapheresis
|
|
Concept
|
Patient Compliance
|
|
Concept
|
Prospective Studies
|
|
Concept
|
Retrospective Studies
|
|
Concept
|
Signal Transduction
|
|
Concept
|
Tumor Suppressor Protein p53
|
|
Concept
|
Fibroblast Growth Factor 2
|
|
Concept
|
Lymphoma, AIDS-Related
|
|
Concept
|
Mice, SCID
|
|
Concept
|
Radiotherapy, Adjuvant
|
|
Concept
|
Estrogen Receptor alpha
|
|
Concept
|
Proto-Oncogene Proteins c-akt
|
|
Concept
|
Young Adult
|
|
Concept
|
Recombinational DNA Repair
|
|
Concept
|
Patient Safety
|
|
Academic Article
|
Phase I study of escalating doses of mitoxantrone and paclitaxel with granulocyte-macrophage colony stimulating factor support.
|
|
Academic Article
|
Peripheral blood mononuclear cell dihydropyrimidine dehydrogenase activity in volunteers with and without diabetes mellitus.
|
|
Academic Article
|
Phase I clinical and pharmacokinetic study of oral 9-aminocamptothecin (NSC-603071).
|
|
Academic Article
|
Phase I study of treatment with oral 13-cis-retinoic acid, subcutaneous interferon alfa-2a, cisplatin, and 24-hour infusion 5-fluorouracil/leucovorin.
|
|
Academic Article
|
Phase II trial of paclitaxel and topotecan with granulocyte colony-stimulating factor support in stage IV breast cancer.
|
|
Academic Article
|
Antifolates: the next generation.
|
|
Academic Article
|
Phase I Trial of ISIS 5132, an antisense oligonucleotide inhibitor of c-raf-1, administered by 24-hour weekly infusion to patients with advanced cancer.
|
|
Academic Article
|
A phase I study of oral uracil/ftorafur (UFT) plus leucovorin and bis-acetato-ammine-dichloro-cyclohexylamine-platinum IV (JM-216) each given over 14 days every 28 days.
|
|
Academic Article
|
Estimation of the effect of food on the disposition of oral 5-fluorouracil in combination with eniluracil.
|
|
Academic Article
|
UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity.
|
|
Academic Article
|
Development of a schedule-dependent population pharmacodynamic model for rhizoxin without quantitation of plasma concentrations.
|
|
Academic Article
|
Human breast cancer susceptibility to paclitaxel therapy is independent of Bcl-2 expression.
|
|
Academic Article
|
A phase I study of liposomal doxorubicin (Doxil) with topotecan.
|
|
Academic Article
|
Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.
|
|
Academic Article
|
Initial clinical experience with intensity-modulated whole-pelvis radiation therapy in women with gynecologic malignancies.
|
|
Academic Article
|
Phase I study of pegylated liposomal doxorubicin, paclitaxel, and cisplatin in patients with advanced solid tumors.
|
|
Academic Article
|
Intensity-modulated whole pelvic radiotherapy in women with gynecologic malignancies.
|
|
Academic Article
|
Invariant p53 immunostaining in primary and recurrent breast cancer.
|
|
Academic Article
|
A phase I and pharmacokinetic study of irinotecan in patients with hepatic or renal dysfunction or with prior pelvic radiation: CALGB 9863.
|
|
Academic Article
|
A phase II trial of docetaxel for peripheral blood stem cell mobilization for patients with breast cancer and ovarian cancer.
|
|
Academic Article
|
Pentostatin pharmacokinetics and dosing recommendations in patients with mild renal impairment.
|
|
Academic Article
|
A phase I trial of pharmacokinetic modulation of carboxyamidotriazole (CAI) with ketoconazole in patients with advanced cancer.
|
|
Academic Article
|
A phase II trial of UFT and leucovorin in women 65 years and older with advanced breast cancer.
|
|
Academic Article
|
A phase I trial of escalating doses of trastuzumab combined with daily subcutaneous interleukin 2: report of cancer and leukemia group B 9661.
|
|
Academic Article
|
In response to Dr. Formenti et al. (Int J Radiat Oncol Biol Phys 2005, 63:1275-1276).
|
|
Academic Article
|
Chemotherapy in endometrial cancer.
|
|
Academic Article
|
Phase I trial of concomitant vinorelbine, cisplatin, and pelvic irradiation in cervical carcinoma and other advanced pelvic malignancies.
|
|
Academic Article
|
Applying a conceptual model for examining health-related quality of life in long-term breast cancer survivors: CALGB study 79804.
|
|
Academic Article
|
Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity.
|
|
Academic Article
|
Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II Consortia.
|
|
Academic Article
|
Administration of glucocorticoids to ovarian cancer patients is associated with expression of the anti-apoptotic genes SGK1 and MKP1/DUSP1 in ovarian tissues.
|
|
Academic Article
|
A phase II study of sorafenib in advanced uterine carcinoma/carcinosarcoma: a trial of the Chicago, PMH, and California Phase II Consortia.
|
|
Academic Article
|
Pharmacokinetic modulation of oral etoposide by ketoconazole in patients with advanced cancer.
|
|
Academic Article
|
A phase I study of sirolimus and bevacizumab in patients with advanced malignancies.
|
|
Academic Article
|
An exploratory analysis of HER-2 amplification and overexpression in advanced endometrial carcinoma: a Gynecologic Oncology Group study.
|
|
Academic Article
|
Dedifferentiated chordoma. Response to aggressive chemotherapy in two cases.
|
|
Academic Article
|
Complementary and alternative medicine use among breast cancer survivors.
|
|
Academic Article
|
Etoposide combined with interferon alfa-2b: novel exploitation of established etoposide pharmacokinetics and pharmacodynamics.
|
|
Academic Article
|
Expedition inspiration consensus 2001.
|
|
Academic Article
|
Phase I study of an oral formulation of ZD9331 administered daily for 28 days.
|
|
Academic Article
|
Phase I and pharmacokinetic study of 24-hour infusion 5-fluorouracil and leucovorin in patients with organ dysfunction.
|
|
Academic Article
|
Concomitant radiation therapy and paclitaxel for unresectable locally advanced breast cancer: results from two consecutive phase I/II trials.
|
|
Academic Article
|
Phase I study of adozelesin administered by 24-hour continuous intravenous infusion.
|
|
Academic Article
|
Racial differences in clinical outcomes from metastatic breast cancer: a pooled analysis of CALGB 9342 and 9840--Cancer and Leukemia Group B.
|
|
Academic Article
|
Two drug interaction studies of sirolimus in combination with sorafenib or sunitinib in patients with advanced malignancies.
|
|
Academic Article
|
Phase II trial of temsirolimus in patients with metastatic breast cancer.
|
|
Academic Article
|
Phase I studies of sirolimus alone or in combination with pharmacokinetic modulators in advanced cancer patients.
|
|
Academic Article
|
Double-blind, randomized crossover study of metoclopramide and batanopride for prevention of cisplatin-induced emesis.
|
|
Academic Article
|
Phase II study of 96-hr continuous-infusion etoposide and doxorubicin with bolus cyclophosphamide in refractory epithelial ovarian cancer.
|
|
Academic Article
|
Phase I trial and pharmacologic trial of sequences of paclitaxel and topotecan in previously treated ovarian epithelial malignancies: a Gynecologic Oncology Group study.
|
|
Academic Article
|
Phase I trial of concomitant chemoradiotherapy for cervical cancer and other advanced pelvic malignancies.
|
|
Academic Article
|
Phase II evaluation of thalidomide in patients with metastatic breast cancer.
|
|
Academic Article
|
Absence of major peripheral neuropathy in a phase II trial of ifosfamide with vinorelbine in patients with ovarian cancer previously treated with platinum and paclitaxel.
|
|
Academic Article
|
Adjuvant aromatase inhibitors: are we there yet?
|
|
Academic Article
|
Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study.
|
|
Academic Article
|
A phase I trial of gemcitabine and topotecan in previously treated ovarian or peritoneal cancer: a Gynecologic Oncology Group study.
|
|
Academic Article
|
A phase I trial of intraperitoneal sustained-release paclitaxel microspheres (Paclimer) in recurrent ovarian cancer: a Gynecologic Oncology Group study.
|
|
Academic Article
|
Interleukin-6, multidrug resistance protein-1 expression and response to paclitaxel in women with metastatic breast cancer: results of cancer and leukemia group B trial 159806.
|
|
Academic Article
|
Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status.
|
|
Academic Article
|
Phase I trial of escalating doses of paclitaxel combined with fixed doses of cisplatin and doxorubicin in advanced endometrial cancer and other gynecologic malignancies: a Gynecologic Oncology Group study.
|
|
Academic Article
|
Systemic therapy for advanced or recurrent endometrial carcinoma.
|
|
Academic Article
|
Gemcitabine/docetaxel--welcome to a new standard.
|
|
Academic Article
|
The impact of sharing results of a randomized breast cancer clinical trial with study participants.
|
|
Academic Article
|
Phase I trial of concomitant vinorelbine, paclitaxel, and pelvic irradiation in cervical carcinoma and other advanced pelvic malignancies.
|
|
Academic Article
|
Re: Response of aleukemic granulocytic sarcoma to all-trans-retinoic acid plus interferon alfa-2a.
|
|
Academic Article
|
Polymorphisms and clinical outcome in recurrent ovarian cancer treated with cyclophosphamide and bevacizumab.
|
|
Academic Article
|
A phase II trial of trastuzumab in combination with low-dose interleukin-2 (IL-2) in patients (PTS) with metastatic breast cancer (MBC) who have previously failed trastuzumab.
|
|
Academic Article
|
The potential benefit of 6 vs. 3 cycles of chemotherapy in subsets of women with early-stage high-risk epithelial ovarian cancer: an exploratory analysis of a Gynecologic Oncology Group study.
|
|
Academic Article
|
Intraperitoneal chemotherapy for ovarian cancer.
|
|
Academic Article
|
Phase III randomized trial of doxorubicin + cisplatin versus doxorubicin + 24-h paclitaxel + filgrastim in endometrial carcinoma: a Gynecologic Oncology Group study.
|
|
Academic Article
|
Rare uterine cancers.
|
|
Academic Article
|
Major progress for a less common cancer.
|
|
Academic Article
|
Racial disparity in survival among patients with advanced/recurrent endometrial adenocarcinoma: a Gynecologic Oncology Group study.
|
|
Academic Article
|
Premenopausal endocrine-responsive early breast cancer: who receives chemotherapy?
|
|
Academic Article
|
Improved surgical outcomes for breast cancer patients receiving neoadjuvant aromatase inhibitor therapy: results from a multicenter phase II trial.
|
|
Academic Article
|
Postmastectomy radiotherapy: clinical practice guidelines of the American Society of Clinical Oncology.
|
|
Academic Article
|
Impact of body mass index on treatment outcomes in endometrial cancer patients receiving doxorubicin and cisplatin: a Gynecologic Oncology Group study.
|
|
Academic Article
|
ENMD-2076, an oral inhibitor of angiogenic and proliferation kinases, has activity in recurrent, platinum resistant ovarian cancer.
|
|
Academic Article
|
Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: a phase 2 randomized study.
|
|
Academic Article
|
A phase I study of weekly temsirolimus and topotecan in the treatment of advanced and/or recurrent gynecologic malignancies.
|
|
Academic Article
|
Barriers to clinical trial participation by older women with breast cancer.
|
|
Academic Article
|
Current treatment of metastatic endometrial cancer.
|
|
Academic Article
|
Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study.
|
|
Academic Article
|
Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342.
|
|
Academic Article
|
Validation and reduction of FACT/GOG-Ntx subscale for platinum/paclitaxel-induced neurologic symptoms: a gynecologic oncology group study.
|
|
Academic Article
|
Systemic chemotherapy for uterine carcinoma: metastatic and adjuvant.
|
|
Academic Article
|
A phase II study single agent of aflibercept (VEGF Trap) in patients with recurrent or metastatic gynecologic carcinosarcomas and uterine leiomyosarcoma. A trial of the Princess Margaret Hospital, Chicago and California Cancer Phase II Consortia.
|
|
Academic Article
|
Management of advanced-stage and recurrent endometrial cancer.
|
|
Academic Article
|
Chemotherapy intensity and toxicity among black and white women with advanced and recurrent endometrial cancer: a Gynecologic Oncology Group Study.
|
|
Academic Article
|
Population analysis of a 24-h paclitaxel infusion in advanced endometrial cancer: a gynaecological oncology group study.
|
|
Academic Article
|
The relationship between histology and outcome in advanced and recurrent endometrial cancer patients participating in first-line chemotherapy trials: a Gynecologic Oncology Group study.
|
|
Academic Article
|
Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia.
|
|
Academic Article
|
Chemo- and radiotherapy in adjuvant management of optimally debulked endometrial cancer.
|
|
Academic Article
|
A phase I trial of the IGF-1R antibody Cixutumumab in combination with temsirolimus in patients with metastatic breast cancer.
|
|
Academic Article
|
Phase I trial of paclitaxel and etoposide for recurrent ovarian carcinoma: a Gynecologic Oncology Group Study.
|
|
Academic Article
|
Meta-analysis of adjuvant cyclophosphamide/methotrexate/5-fluorouracil chemotherapy in postmenopausal women with estrogen receptor-positive, node-positive breast cancer.
|
|
Academic Article
|
A phase II study of ramucirumab (IMC-1121B) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma.
|
|
Academic Article
|
A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer.
|
|
Academic Article
|
Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study.
|
|
Academic Article
|
Randomized Trial of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers, or BRCA-Mutant Ovarian Cancer.
|
|
Academic Article
|
Megestrol acetate reverses multidrug resistance and interacts with P-glycoprotein.
|
|
Academic Article
|
Treatment of ovarian cancer in the older woman.
|
|
Academic Article
|
Neo-adjuvant capecitabine chemotherapy in women with newly diagnosed locally advanced breast cancer in a resource-poor setting (Nigeria): efficacy and safety in a phase II feasibility study.
|
|
Academic Article
|
A phase II study of single-agent RO4929097, a gamma-secretase inhibitor of Notch signaling, in patients with recurrent platinum-resistant epithelial ovarian cancer: A study of the Princess Margaret, Chicago and California phase II consortia.
|
|
Academic Article
|
Leptomeningeal carcinomatosis from breast cancer treated with intrathecal topotecan with concomitant intravenous eribulin.
|
|
Academic Article
|
Temsirolimus with or without megestrol acetate and tamoxifen for endometrial cancer: a gynecologic oncology group study.
|
|
Academic Article
|
Risk factors for GI adverse events in a phase III randomized trial of bevacizumab in first-line therapy of advanced ovarian cancer: A Gynecologic Oncology Group Study.
|
|
Academic Article
|
The role of postoperative radiation therapy for endometrial cancer: Executive summary of an American Society for Radiation Oncology evidence-based guideline.
|
|
Academic Article
|
A phase II trial of sunitinib in women with metastatic or recurrent endometrial carcinoma: a study of the Princess Margaret, Chicago and California Consortia.
|
|
Academic Article
|
Adjuvant exemestane with ovarian suppression in premenopausal breast cancer.
|
|
Academic Article
|
Circadian variation in plasma 5-fluorouracil concentrations during a 24 hour constant-rate infusion.
|
|
Academic Article
|
Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials.
|
|
Academic Article
|
A phase 2 study of cediranib in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: a trial of the Princess Margaret, Chicago and California Phase II Consortia.
|
|
Academic Article
|
Sustained Complete Response to Cytotoxic Therapy and the PARP Inhibitor Veliparib in Metastatic Castration-Resistant Prostate Cancer - A Case Report.
|
|
Academic Article
|
Glucocorticoid receptor activation inhibits chemotherapy-induced cell death in high-grade serous ovarian carcinoma.
|
|
Academic Article
|
Ascites predicts treatment benefit of bevacizumab in front-line therapy of advanced epithelial ovarian, fallopian tube and peritoneal cancers: an NRG Oncology/GOG study.
|
|
Academic Article
|
Serum C-Telopeptide Collagen Crosslinks and Plasma Soluble VEGFR2 as Pharmacodynamic Biomarkers in a Trial of Sequentially Administered Sunitinib and Cilengitide.
|
|
Academic Article
|
Chemotherapy-induced peripheral neuropathy: Current status and progress.
|
|
Academic Article
|
Association of Metformin Use with Outcomes in Advanced Endometrial Cancer Treated with Chemotherapy.
|
|
Academic Article
|
Adjuvant ovarian suppression in premenopausal breast cancer.
|
|
Academic Article
|
Predictive value and clinical utility of centrally assessed ER, PgR, and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer: TEXT and SOFT trials.
|
|
Academic Article
|
Tumor mutational analysis of GOG248, a phase II study of temsirolimus or temsirolimus and alternating megestrol acetate and tamoxifen for advanced endometrial cancer (EC): An NRG Oncology/Gynecologic Oncology Group study.
|
|
Academic Article
|
The Application and Outcome of Standard of Care Treatment in Elderly Women with Ovarian Cancer: A Literature Review over the Last 10 Years.
|
|
Academic Article
|
Adjuvant ovarian function suppression and cognitive function in women with breast cancer.
|
|
Academic Article
|
Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function Trial.
|
|
Academic Article
|
Twelve-Month Estrogen Levels in Premenopausal Women With Hormone Receptor-Positive Breast Cancer Receiving Adjuvant Triptorelin Plus Exemestane or Tamoxifen in the Suppression of Ovarian Function Trial (SOFT): The SOFT-EST Substudy.
|
|
Academic Article
|
Absolute Benefit of Adjuvant Endocrine Therapies for Premenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer: TEXT and SOFT Trials.
|
|
Academic Article
|
New drugs in ovarian cancer.
|
|
Academic Article
|
No Exit: Identifying Avoidable Terminal Oncology Intensive Care Unit Hospitalizations.
|
|
Academic Article
|
Chemotherapy for Endometrial Cancer in Adjuvant and Advanced Disease Settings.
|
|
Academic Article
|
Reply to F. Tomao et al.
|
|
Academic Article
|
Postmastectomy Radiotherapy: An American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Focused Guideline Update.
|
|
Academic Article
|
New biomarkers for the prediction of spontaneous preterm labour in symptomatic pregnant women: a comparison with fetal fibronectin.
|
|
Academic Article
|
Implementation of timeline reforms speeds initiation of National Cancer Institute-sponsored trials.
|
|
Academic Article
|
Nasopharyngeal mass: a manifestation of inflammatory otologic disease.
|
|
Academic Article
|
The best of times...the worst of times.
|
|
Academic Article
|
Survey of oncologists' perceptions of barriers to accrual of older patients with breast carcinoma to clinical trials.
|
|
Academic Article
|
Adjuvant treatment of premenopausal women with endocrine-responsive early breast cancer: design of the TEXT and SOFT trials.
|
|
Academic Article
|
Association between human immunodeficiency virus type 1 infection and cancer in the black population of Johannesburg and Soweto, South Africa.
|
|
Academic Article
|
Reply to L.B. Marks et al.
|
|
Academic Article
|
A phase I trial of scutellaria barbata (BZL101) for metastatic breast cancer.
|
|
Academic Article
|
Characterization of T cell repertoire of blood, tumor, and ascites in ovarian cancer patients using next generation sequencing.
|
|
Academic Article
|
Sorafenib (SOR) in patients (pts) with advanced/recurrent uterine carcinoma (UCA) or carcinosarcoma (CS): A phase II trial of the University of Chicago, PMH, and California Phase II Consortia.
|
|
Academic Article
|
A phase II study of cediranib (AZD2171) in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: Final results of a PMH, Chicago and California consortia trial.
|
|
Academic Article
|
A phase II trial of bryostatin in combination with cisplatin in patients with recurrent or persistent epithelial ovarian cancer: A California cancer consortium (CCC) trial.
|
|
Academic Article
|
Chemotherapy completion in elderly women with ovarian, primary peritoneal or fallopian tube cancer - An NRG oncology/Gynecologic Oncology Group study.
|
|
Academic Article
|
A drug interaction study of sorafenib (S) and rapamycin (R) in patients with advanced malignancies.
|
|
Academic Article
|
Interim report of a phase II clinical trial of bevacizumab (Bev) and low dose metronomic oral cyclophosphamide (mCTX) in recurrent ovarian (OC) and primary peritoneal carcinoma: A California Cancer Consortium Trial.
|
|
Academic Article
|
High stathmin expression is a marker for poor clinical outcome in endometrial cancer: An NRG oncology group/gynecologic oncology group study.
|
|
Academic Article
|
High glucocorticoid receptor expression predicts short progression-free survival in ovarian cancer.
|
|
Academic Article
|
Induction of Neoantigen-Specific Cytotoxic T Cells and Construction of T-cell Receptor-Engineered T Cells for Ovarian Cancer.
|
|
Academic Article
|
An evaluation of progression free survival and overall survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: An NRG Oncology/Gynecologic Oncology Group experience.
|
|
Academic Article
|
Pre-operative assessment and post-operative outcomes of elderly women with gynecologic cancers, primary analysis of NRG CC-002: An NRG oncology group/gynecologic oncology group study.
|
|
Academic Article
|
Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors.
|
|
Academic Article
|
Expression of glucocorticoid receptor is associated with aggressive primary endometrial cancer and increases from primary to metastatic lesions.
|
|
Academic Article
|
Hormone Therapy plus mTOR Inhibitors in the Treatment of Endometrial Carcinoma.
|
|
Academic Article
|
A Phase I Clinical Trial of Guadecitabine and Carboplatin in Platinum-Resistant, Recurrent Ovarian Cancer: Clinical, Pharmacokinetic, and Pharmacodynamic Analyses.
|
|
Academic Article
|
Association of Ipilimumab With Safety and Antitumor Activity in Women With Metastatic or Recurrent Human Papillomavirus-Related Cervical Carcinoma.
|
|
Academic Article
|
Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer.
|
|
Academic Article
|
Comparison of the incidence of febrile neutropenia in obese and normal weight breast cancer patients receiving myelosuppressive chemotherapy and prophylactic pegfilgrastim.
|
|
Academic Article
|
Phase I combination study of the PARP inhibitor veliparib plus carboplatin and gemcitabine in patients with advanced ovarian cancer and other solid malignancies.
|
|
Academic Article
|
Discovery of a Glucocorticoid Receptor (GR) Activity Signature Using Selective GR Antagonism in ER-Negative Breast Cancer.
|
|
Academic Article
|
Adjuvant Systemic Treatment of Premenopausal Women With Hormone Receptor-Positive Early Breast Cancer: Lights and Shadows.
|
|
Academic Article
|
Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial.
|
|
Academic Article
|
Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study.
|
|
Academic Article
|
Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer.
|
|
Academic Article
|
Phase II Study of Avelumab in Patients With Mismatch Repair Deficient and Mismatch Repair Proficient Recurrent/Persistent Endometrial Cancer.
|
|
Academic Article
|
Myasthenia gravis induced by avelumab.
|
|
Academic Article
|
Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer.
|
|
Academic Article
|
Absolute Improvements in Freedom From Distant Recurrence to Tailor Adjuvant Endocrine Therapies for Premenopausal Women: Results From TEXT and SOFT.
|
|
Academic Article
|
A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer.
|
|
Academic Article
|
Phase II Trial of Cabozantinib in Recurrent/Metastatic Endometrial Cancer: A Study of the Princess Margaret, Chicago, and California Consortia (NCI9322/PHL86).
|
|
Academic Article
|
A Phase 1 Trial Assessing the Safety and Tolerability of a Therapeutic DNA Vaccination Against HPV16 and HPV18 E6/E7 Oncogenes After Chemoradiation for Cervical Cancer.
|
|
Academic Article
|
Therapeutic Targets and Opportunities in Endometrial Cancer: Update on Endocrine Therapy and Nonimmunotherapy Targeted Options.
|
|
Academic Article
|
Treatment-induced symptoms, depression and age as predictors of sexual problems in premenopausal women with early breast cancer receiving adjuvant endocrine therapy.
|
|
Academic Article
|
Clinical evaluation of germline polymorphisms associated with capecitabine toxicity in breast cancer: TBCRC-015.
|
|
Academic Article
|
Tamrintamab pamozirine (SC-003) in patients with platinum-resistant/refractory ovarian cancer: Findings of a phase 1 study.
|
|
Academic Article
|
Immune checkpoint inhibitors in women with gynecologic cancers: Practical considerations.
|
|
Academic Article
|
Improved Survival Associated with Local Tumor Response Following Multisite Radiotherapy and Pembrolizumab: Secondary Analysis of a Phase I Trial.
|
|
Academic Article
|
Health-related quality of life outcomes for the LEAP study-CALGB 70305 (Alliance): A lymphedema prevention intervention trial for newly diagnosed breast cancer patients.
|
|
Academic Article
|
Carboplatin and Paclitaxel for Advanced Endometrial Cancer: Final Overall Survival and Adverse Event Analysis of a Phase III Trial (NRG Oncology/GOG0209).
|
|
Academic Article
|
A randomized study to prevent lymphedema in women treated for breast cancer: CALGB 70305 (Alliance).
|
|
Academic Article
|
Racial disparities in survival outcomes among breast cancer patients by molecular subtypes.
|
|
Academic Article
|
Implementation of pharmacogenomic testing in oncology care (PhOCus): study protocol of a pragmatic, randomized clinical trial.
|
|
Academic Article
|
Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial.
|
|
Academic Article
|
Impact of post-diagnosis weight change on survival outcomes in Black and White breast cancer patients.
|
|
Academic Article
|
Progression-free survival by investigator versus blinded independent central review in newly diagnosed patients with high-grade serous ovarian cancer: Analysis of the VELIA/GOG-3005 trial.
|
|
Academic Article
|
Phase I Study of Stereotactic Body Radiotherapy plus Nivolumab and Urelumab or Cabiralizumab in Advanced Solid Tumors.
|
|
Academic Article
|
Successful treatment of squamous cell carcinoma arising from a presumed ovarian mature cystic teratoma with pembrolizumab.
|
|
Academic Article
|
Small cell carcinoma of the ovary, pulmonary type: A role for adjuvant radiotherapy after carboplatin and etoposide?
|
|
Academic Article
|
High glucocorticoid receptor expression in the sarcomatous versus carcinomatous elements of Mullerian carcinosarcomas.
|
|
Academic Article
|
Epigenetic priming enhances antitumor immunity in platinum-resistant ovarian cancer.
|
|
Academic Article
|
Evaluation of Treatment With Talazoparib and Avelumab in Patients With Recurrent Mismatch Repair Proficient Endometrial Cancer.
|
|
Concept
|
Poly(ADP-ribose) Polymerase Inhibitors
|
|
Concept
|
Bevacizumab
|
|
Concept
|
Trastuzumab
|
|
Concept
|
Erlotinib Hydrochloride
|
|
Concept
|
Ipilimumab
|
|
Concept
|
MCF-7 Cells
|
|
Concept
|
Febrile Neutropenia
|
|
Concept
|
Drug-Related Side Effects and Adverse Reactions
|
|
Concept
|
Cytoreduction Surgical Procedures
|
|
Academic Article
|
The Impact of Race and Age on Response to Neoadjuvant Therapy and Long-Term Outcomes in Black and White Women with Early-Stage Breast Cancer.
|
|
Academic Article
|
Impact of homologous recombination status and responses with veliparib combined with first-line chemotherapy in ovarian cancer in the Phase 3 VELIA/GOG-3005 study.
|
|
Academic Article
|
Impact of veliparib, paclitaxel dosing regimen, and germline BRCA status on the primary treatment of serous ovarian cancer - an ancillary data analysis of the VELIA trial.
|
|
Academic Article
|
Translational randomized phase II trial of cabozantinib in combination with nivolumab in advanced, recurrent, or metastatic endometrial cancer.
|
|
Academic Article
|
Overcoming Taxane Resistance: Preclinical and Phase 1 Studies of Relacorilant, a Selective Glucocorticoid Receptor Modulator, with Nab-Paclitaxel in Solid Tumors.
|
|
Academic Article
|
CA-125 KELIM as a Potential Complementary Tool for Predicting Veliparib Benefit: An Exploratory Analysis From the VELIA/GOG-3005 Study.
|
|
Academic Article
|
Identification of Patients With Ovarian Cancer Experiencing the Highest Benefit From Bevacizumab in the First-Line Setting on the Basis of Their Tumor-Intrinsic Chemosensitivity (KELIM): The GOG-0218 Validation Study.
|
|
Academic Article
|
Adjuvant Endocrine Therapy in Premenopausal Breast Cancer: 12-Year Results From SOFT.
|
|
Academic Article
|
Adjuvant Exemestane With Ovarian Suppression in Premenopausal Breast Cancer: Long-Term Follow-Up of the Combined TEXT and SOFT Trials.
|
|
Academic Article
|
Relacorilant + Nab-Paclitaxel in Patients With Recurrent, Platinum-Resistant Ovarian Cancer: A Three-Arm, Randomized, Controlled, Open-Label Phase II Study.
|
|
Academic Article
|
Personalizing Adjuvant Endocrine Therapy for Early-Stage Hormone Receptor-Positive Breast Cancer.
|
|
Academic Article
|
Stress, Isolation, and Sleep Quality among Breast Cancer Survivors throughout the COVID-19 Pandemic: A Longitudinal Study in a Multi-Ethnic Cohort.
|
|
Academic Article
|
Flashback Foreword: Concurrent Chemotherapy/Radiotherapy for Cervical Cancer.
|
|
Academic Article
|
Remotely Delivered Cancer Genetic Testing in the Making Genetic Testing Accessible (MAGENTA) Trial: A Randomized Clinical Trial.
|
|
Academic Article
|
Validation of the RSClin risk calculator in the National Cancer Data Base.
|